# DAN-222

Source: https://onco.cc/drugs/dan-222/  
OnCo record `dan-222` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DAN-222 is an experimental high-capacity drug conjugate from Dantari, in phase 2 trials for HER2-negative metastatic breast cancer; its current status is not stated.

## Summary

DAN-222 is a high-capacity drug conjugate (polymer-based) from Dantari. A high-capacity drug conjugate carrying a topoisomerase 1 inhibitor payload. Its furthest stage is phase 2, for HER2-negative metastatic breast cancer. ClinicalTrials.gov registers it in 2 studies linked below. Own phase 1 NCT05261269 completed; the I-SPY phase 2 platform arm 'Dan222 + Niraparib' is closed. Company status not verified (domain parked). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: DAN-222
- Modality: High-capacity drug conjugate (polymer-based)
- Mechanism: A high-capacity drug conjugate carrying a topoisomerase 1 inhibitor payload.

## Sources

- Dantari: biospace.com: https://www.biospace.com/dantari-launches-with-47m-to-make-better-adcs
- Dantari: biopharmadive.com: https://www.biopharmadive.com/news/dantari-launch-cancer-drug-conjugates/638266/
- Dantari: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT05261269
- Dantari: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT01042379
- ClinicalTrials.gov: trials of DAN-222: https://clinicaltrials.gov/search?intr=DAN-222

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- companies: [Dantari](https://onco.cc/companies/dantari/)
- trials: [A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer](https://onco.cc/trials/nct05261269/), [I-SPY 2.2](https://onco.cc/trials/i-spy-2-2/)

---
JSON: https://onco.cc/api/v1/entities/dan-222.json